Patents Assigned to ModernaTX, Inc.
  • Patent number: 11911474
    Abstract: Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: February 27, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Antonin De Fougerolles, Sayda M. Elbashir
  • Patent number: 11911453
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: February 27, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw
  • Patent number: 11912982
    Abstract: Aspects of the disclosure relate to liquid chromatography (e.g., HPLC) methods which enable high resolution separations of polynucleotides having hydrophobic portions (e.g., polyadenylated nucleic acids, such as mRNA) based upon the hydrophobic character of the molecules (e.g., polyA tail length). In some embodiments, the disclosure describes liquid chromatographic methods for separating a nucleic acid having a hydrophobic portion (e.g., a polyadenylated nucleic acid, such as an mRNA) from a complex mixture by a mobile phase system that comprises an ion pairing agent selected from Tris, inorganic cations (including e.g., Na, Li, K, ammonium, etc.), biological buffers (e.g., MOPS, HEPES, PIPES, etc.), and other charged or hydrophilic moieties, and lacks conventional ion pairing agents (e.g., Triethylammonium acetate, TEAA). Accordingly, in some embodiments methods described by the disclosure are useful for assessing the quality of pharmaceutical preparations comprising nucleic acids.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: February 27, 2024
    Assignee: ModernaTX, Inc.
    Inventors: William Issa, Meredith Packer
  • Patent number: 11905525
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering nucleic acids in vivo. These compositions have reduced immune activation resulting in accelerated blood clearance and/or anti-drug antibodies and they have an improved toxicity profile and therapeutic index in vivo.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: February 20, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Luis Brito, Gilles Besin
  • Publication number: 20240025935
    Abstract: The present invention relates to compositions and methods for the purification of ribonucleic acids including a polyA tail. The compositions and methods include a polystyrene divinylbenzene particle, a linker, and a poly-deoxythymidine oligonucleotide.
    Type: Application
    Filed: November 18, 2021
    Publication date: January 25, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Bill KELLEHER, Michael SHAMASHKIN
  • Publication number: 20240016827
    Abstract: Provided herein are compositions and methods of reducing adduct formation.
    Type: Application
    Filed: June 2, 2023
    Publication date: January 18, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Meredith Packer, Dipendra Gyawali, Serenus Hua, Gabor Butora, Gregory John Mercer
  • Patent number: 11873327
    Abstract: The present disclosure relates to polynucleotides encoding tethered interleukin-12 (IL-12) polypeptides comprising an IL-12 polypeptide and a membrane domain. The present disclosure also relates to vectors comprising the polynucleotides; host cells comprising the polynucleotides or vectors, polypeptides encoded by the polynucleotides; compositions comprising the polynucleotides, vectors, host cells, or polypeptides and a delivery agent; and uses thereof, including treatment of cancer.
    Type: Grant
    Filed: July 28, 2022
    Date of Patent: January 16, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Ankita Mishra, Joshua Frederick, Sushma Gurumurthy
  • Patent number: 11872278
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: January 16, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Patent number: 11866696
    Abstract: Aspects of the disclosure relate to liquid chromatography (e.g., HPLC) methods which enable high resolution separations of polynucleotides of various lengths, sequences, and/or base compositions in a highly tunable manner. In some embodiments, the disclosure describes liquid chromatographic methods for separating a nucleic acid (e.g., a polyadenylated nucleic acid, such as an mRNA) from a complex mixture by using multiple ion pairing agents in the same mobile phase system. Accordingly, in some embodiments methods described by the disclosure are useful for assessing the quality of pharmaceutical preparations comprising nucleic acids.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: January 9, 2024
    Assignee: ModernaTX, Inc.
    Inventors: William Issa, Meredith Packer
  • Patent number: 11866754
    Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: January 9, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Gabor Butora, Matthew Stanton, Edward John Miracco
  • Patent number: 11866475
    Abstract: The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and formulations comprising the modified RNA. Aspects of the disclosure further relate to preparations and uses of formulations comprising the modified RNA in treating subjects suffering from diseases responsive to VEGF-A therapy.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: January 9, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Leif Karlsson Parinder, Regina Desirée Fritsche Danielson, Kenny Mikael Hansson, Li Ming Gan, Jonathan Clarke, Ann-Charlotte Eva Egnell, Kenneth Randall Chien
  • Publication number: 20240000917
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
    Type: Application
    Filed: May 24, 2023
    Publication date: January 4, 2024
    Applicant: ModernaTX, Inc.
    Inventor: Giuseppe Ciaramella
  • Patent number: 11859215
    Abstract: This disclosure relates mRNA therapy for the treatment of ornithine transcarbamylase deficiency (OTCD). mRNAs for use in the invention, when administered in vivo, encode human ornithine transcarbamylase (OTC), isoforms thereof, functional fragments thereof, and fusion proteins comprising OTC. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of OTC expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic ammonia associated with deficient OTC activity in subjects.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: January 2, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Zhijian Zhuo, Andrea Lea Frassetto, Paolo G. V. Martini, Vladimir Presnyak, Patrick Finn
  • Patent number: 11851694
    Abstract: The present disclosure provides methods and compositions for high fidelity in vitro transcription reactions.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: December 26, 2023
    Assignee: ModernaTX, Inc.
    Inventors: David Mauger, Vladimir Presnyak, Amy E. Rabideau, Iain Mcfadyen
  • Patent number: 11845772
    Abstract: Disclosed herein are methods for purifying RNA comprising poly A. Also disclosed herein are compositions such as surfaces and oligonucleotides for purifying RNA comprising polyA. Other embodiments are also disclosed. Commercially-available resins having polythymidine oligonucleotide ligands typically contain less than 30 thymidine (2?deoxy) residues and some commercial resin suppliers utilize a distribution of dT chain lengths, not of a discreet length.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: December 19, 2023
    Assignee: ModernaTX, Inc.
    Inventors: William Joseph Issa, John Grant Aunins, Stephane Bancel
  • Publication number: 20230390379
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: May 10, 2023
    Publication date: December 7, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
  • Publication number: 20230381301
    Abstract: Provided herein, in some embodiments, are vaccines (and vaccination methods) that include a ribonucleic acid (RNA) polynucleotide encoding a human metapneumovirus (hMPV) F protein and a RNA polynucleotide encoding a human parainfluenza virus 3 (hPIV3) F protein.
    Type: Application
    Filed: March 24, 2023
    Publication date: November 30, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Publication number: 20230374079
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: August 4, 2023
    Publication date: November 23, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sayda Mahgoub Elbashir
  • Publication number: 20230355743
    Abstract: The disclosure provides coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: September 24, 2021
    Publication date: November 9, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Guillaume Stewart-Jones, Mihir Metkar, Vladimir Presnyak
  • Publication number: 20230346907
    Abstract: The disclosure relates to sexually transmitted disease ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: April 24, 2023
    Publication date: November 2, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu